These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 17297401)

  • 1. Long-term graft outcomes after steroid withdrawal in African American kidney transplant recipients receiving sirolimus and tacrolimus.
    Hricik DE; Augustine JJ; Knauss TC; Bodziak KA; Aeder M; Siegel C; Schulak JA
    Transplantation; 2007 Feb; 83(3):277-81. PubMed ID: 17297401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Withdrawal of steroid therapy in African American kidney transplant recipients receiving sirolimus and tacrolimus.
    Hricik DE; Knauss TC; Bodziak KA; Weigel K; Rodriguez V; Seaman D; Siegel C; Valente J; Schulak JA
    Transplantation; 2003 Sep; 76(6):938-42. PubMed ID: 14508357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
    Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
    Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome after steroid withdrawal in pediatric renal transplant patients receiving tacrolimus-based immunosuppression.
    Chakrabarti P; Wong HY; Scantlebury VP; Jordan ML; Vivas C; Ellis D; Lombardozzi-Lane S; Hakala TR; Fung JJ; Simmons RL; Starzl TE; Shapiro R
    Transplantation; 2000 Sep; 70(5):760-4. PubMed ID: 11003353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter pilot study of early (4-day) steroid cessation in renal transplant recipients under simulect, tacrolimus and sirolimus.
    Woodle ES; Vincenti F; Lorber MI; Gritsch HA; Hricik D; Washburn K; Matas AJ; Gallichio M; Neylan J
    Am J Transplant; 2005 Jan; 5(1):157-66. PubMed ID: 15636625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Comparative Effectiveness Analysis of Early Steroid Withdrawal in Black Kidney Transplant Recipients.
    Taber DJ; Hunt KJ; Gebregziabher M; Srinivas T; Chavin KD; Baliga PK; Egede LE
    Clin J Am Soc Nephrol; 2017 Jan; 12(1):131-139. PubMed ID: 27979979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of African American kidney transplant recipients treated with sirolimus, tacrolimus, and corticosteroids.
    Hricik DE; Anton HA; Knauss TC; Rodriguez V; Seaman D; Siegel C; Valente J; Schulak JA
    Transplantation; 2002 Jul; 74(2):189-93. PubMed ID: 12151730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of pancreas transplantation after steroid withdrawal under tacrolimus immunosuppression.
    Jordan ML; Chakrabarti P; Luke P; Shapiro R; Vivas CA; Scantlebury VP; Fung JJ; Starzl TE; Corry RJ
    Transplantation; 2000 Jan; 69(2):265-71. PubMed ID: 10670637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Freedom from rejection and stable kidney function are excellent criteria for steroid withdrawal in tacrolimus-treated kidney transplant recipients.
    Włodarczyk Z; Wałaszewski J; Perner F; Vitko S; Ostrowski M; Bachleda P; Kokot F; Klinger M; Szenohradsky P; Studenik P; Navratil P; Asztalos L; Rutkowski B; Nagy KK; Hickey D
    Ann Transplant; 2002; 7(3):28-31. PubMed ID: 12465429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
    Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
    Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. De novo use of sirolimus in immunosuppression regimens in kidney and kidney-pancreas transplantation at the University of California, San Francisco.
    Vincenti F; Stock P
    Transplant Proc; 2003 May; 35(3 Suppl):183S-186S. PubMed ID: 12742494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of early conversion from tacrolimus to sirolimus on chronic allograft changes in kidney recipients on rapid steroid withdrawal.
    Heilman RL; Cortese C; Geiger XJ; Younan K; Wadei HM; Mai ML; Reddy KS; Gonwa TA
    Transplantation; 2012 Jan; 93(1):47-53. PubMed ID: 22067270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alemtuzumab preconditioning allows steroid-calcineurin inhibitor-free regimen in live-donor kidney transplant.
    Refaie AF; Mahmoud KM; Ismail AM; Sheashaa HA; Kamal AI; Ghoneim MA
    Exp Clin Transplant; 2011 Oct; 9(5):295-301. PubMed ID: 21967254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of African-American kidney-transplant recipients treated with sirolimus, tacrolimus, and corticosteroids.
    Egidi MF; Gaber AO
    Transplantation; 2003 Feb; 75(4):572; author reply 573. PubMed ID: 12605133
    [No Abstract]   [Full Text] [Related]  

  • 17. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial.
    Thomusch O; Wiesener M; Opgenoorth M; Pascher A; Woitas RP; Witzke O; Jaenigen B; Rentsch M; Wolters H; Rath T; Cingöz T; Benck U; Banas B; Hugo C
    Lancet; 2016 Dec; 388(10063):3006-3016. PubMed ID: 27871759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of TOR inhibitors and other immunosuppressive regimens in African-American renal transplant recipients.
    Hricik DE
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 2):S11-5. PubMed ID: 11583939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sirolimus improves the two-year outcome of renal allografts in African-American patients.
    Podder H; Podbielski J; Hussein I; Katz S; Van Buren C; Kahan BD
    Transpl Int; 2001 Jun; 14(3):135-42. PubMed ID: 11499902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Observations regarding the use of sirolimus and tacrolimus in high-risk cadaveric renal transplantation.
    Lo A; Egidi MF; Gaber LW; Shokouh-Amiri MH; Nazakatgoo N; Fisher JS; Gaber AO
    Clin Transplant; 2004 Feb; 18(1):53-61. PubMed ID: 15108771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.